OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.

Consulting Report
November 2015

The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.

O'Neill, P. and Sussex, J.

Consulting Report
May 2015

The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.

Karlsberg Schaffer, S., Sussex, J., Hughes, D. and Devlin, N.

Research Paper
June 2014

This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies recommended by NICE within three months after NICE publishes a Technology Appraisal (TA). Based on interviews with medical and/or finance directors of the seven Wales LHBs, the study covers the period from October 2010 through March 2013.

Chambers, J.

Seminar Briefing
March 2014

Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, considers the current use of cost-effectiveness analysis in the US and explores the potential value of including it in decisions about coverage for medical technology by Medicare (the national public health insurance programme primarily for people 65+ years of age).

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J.

Research Paper
January 2014

The Pharmaceutical Price Regulation Scheme (PPRS) 2014 Heads of Agreement, announced on 6 November 2013, outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time, the PPRS caps future growth in the NHS's branded medicines bill, between 2014 and 2018.

Karlsberg Schaffer, S., Sussex, J., Devlin, N. and Walker, A.

Research Paper
December 2013

This research examines the use of QALY thresholds in NHS Scotland in 2012-13 for health services that were "at the margin", i.e. those for which investment or disinvestment was planned or occurred.

The study was based on information from three sources: public information from the Scottish Parliament's examination of the NHS Boards' expenditure plans, interviews with the Finance Directors of Scotland's territorial NHS Boards, and a literature review.

Mattison, N. ed.

Monograph
July 2013

Based on OHE’s 50th anniversary conference, this publication captures the views of thought leaders from around the world about the scientific and economic climate for drug development by 2022.

Four major themes stood out in the conference discussions, as reported in this publication.

1. Health care will be radically transformed as “precision” medicine plugs into the specific  genetic makeup of both patients and diseases, and is paired with increasingly powerful and convenient diagnostics.

Pages